This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (July 2018)
This article's tone or style may not reflect the encyclopedic tone used on Wikipedia. See Wikipedia's guide to writing better articles for suggestions.(January 2020) (Learn how and when to remove this message)
Afamelanotide, sold under the brand name Scenesse, is a medication used to prevent phototoxicity and to reduce pain from light exposure for people with erythropoietic protoporphyria.[1][2][4] It is a melanocortin 1 receptor (MC1-R) agonist[1] and a synthetic peptide and analogue of α-melanocyte stimulating hormone.[1] It is administered as subcutaneous implant.[3]
The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[5]
^ abcd"Scenesse- afamelanotide implant". DailyMed. U.S. National Library of Medicine. 15 May 2023. Archived from the original on 25 July 2022. Retrieved 15 June 2023.
^ abCite error: The named reference Scenesse EPAR was invoked but never defined (see the help page).
^ abCite error: The named reference EMA2017 was invoked but never defined (see the help page).
^Cite error: The named reference FDA Snapshot was invoked but never defined (see the help page).
^"New Drug Therapy Approvals 2019". U.S. Food and Drug Administration. 31 December 2019. Archived from the original on 16 September 2020. Retrieved 15 September 2020.
Afamelanotide, sold under the brand name Scenesse, is a medication used to prevent phototoxicity and to reduce pain from light exposure for people with...
nausea and vomiting. As a tanning agent, melanotan I (now known as afamelanotide) was licensed by Competitive Technologies, a technology transfer company...
and racist antics in nearly every episode. As of July 2013[update], afamelanotide is in phase II and III clinical trials for vitiligo and other skin diseases...
Retrieved 2020-09-24. "Scenesse (afamelanotide) for adults with a history of phototoxic reactions from EPP". SCENESSE® (Afamelanotide). Retrieved 2020-09-24. Kraemer...
peptide and agouti-related peptide, and activated by synthetic (i.e. afamelanotide) and endogenous agonist melanocyte-stimulating hormones. Several selective...
other peptide analogues of the same family as bremelanotide include afamelanotide (NDP-α-MSH), modimelanotide, and setmelanotide. Studies in the early...
Melanotan may refer to one of two separate peptides: Afamelanotide, originally developed under the names "Melanotan", "Melanotan-1", or "Melanotan I"...
several analogs, including afamelanotide, then called melanotan-I. In the European Union and United States, afamelanotide is indicated for the prevention...
approved for chronic weight management in patients with genetic obesity. Afamelanotide (Scenesse) is an MC1R agonist approved for patients with erythropoietic...
Unless there is liver failure, it is not a life-threatening disease. Afamelanotide, developed by Australian-based Clinuvel Pharmaceuticals, was approved...
should suggest likely mechanisms of this interaction.[citation needed] Afamelanotide Agouti-related peptide Melanocortin Melanotan II GRCh38: Ensembl release...
although long-term results are not yet available. In December 2014, afamelanotide received authorization from the European Commission as a treatment for...
erectile dysfunction. The non-selective melanocortin receptor agonist afamelanotide (NDP-α-MSH) has been found to induce brain-derived neurotrophic factor...
Global Information
(what is this?) (verify)